Annual banned-substance review 16th edition - Analytical approaches in human sports drug testing 2022/2023 / Mario Thevis, Tiia Kuuranne, Hans Geyer
- Drug Testing and Analysis 16 (2024) 1 (January), p. 5-29
- PMID: 37985429
- DOI: 10.1002/dta.3602
Contents:
- Introduction
- Anabolic Agent
- Anabolic-androgenic steroids (AASs)
- Initial testing procedures (ITPs)—
Comprehensive screening and metabolism studies - Other anabolic agents
- Steroid profiling in urine and blood
- Confirmatory testing procedures—Isotope
ratio mass spectrometry (IRMS)
- Peptide Hormones, Growth Factors, Related Substances, and Mimetics
- EPO-receptor agonists (ERAs) and hypoxia-inducible
factor (HIF) activating agents - Peptide hormones and their releasing factors,
growth factors, and growth factor modulators
- EPO-receptor agonists (ERAs) and hypoxia-inducible
-
Β2-Agonists, Hormone, And Metabolic Modulators
- β2-Agonists
- Hormone and metabolic modulators
- Diuretics And Masking Agents,
- Stimulants And Narcotics
- Glucocorticoids, Cannabinoids, And Beta-Blockers
- Manipulation Of Blood And Blood Components
- Gene Doping
- Conclusion And Perspectives
Abstract
In this 16th edition of the annual banned-substance review on analytical approaches in human sports drug testing, literature on recent developments in this particular section of global anti-doping efforts that was published between October 2022 and September 2023 is summarized and discussed. Most recent additions to the continuously growing portfolio of doping control analytical approaches and investigations into analytical challenges in the context of adverse analytical findings are presented, taking into account existing as well as emerging challenges in anti-doping, with specific focus on substances and methods of doping recognized in the World Anti-Doping Agency's 2023 Prohibited List. As in previous years, focus is put particularly on new or enhanced analytical options in human doping controls, appreciating the exigence and core mission of anti-doping and, equally, the conflict arising from the opposingly trending extent of the athlete's exposome and the sensitivity of instruments nowadays commonly available in anti-doping laboratories.
